Advertisement

Topics

Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Pipeline Review, H1 2018 [Report Updated: 20022018] Prices from USD $3500

04:51 EDT 14 Mar 2018 | BioPortfolio Report Blog

Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Pipeline Review, H1 2018


Summary


According to the recently published report 'Metabotropic Glutamate Receptor 3 Pipeline Review, H1 2018'; Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.


Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Metabotropic glutamate receptor 3 is a G proteincoupled receptor encoded by the GRM3 gene. Lglutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.


The report 'Metabotropic Glutamate Receptor 3 Pipeline Review, H1 2018' outlays comprehensive information on the Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Oncology which include indications Depression, Anxiety Disorders, Attention Deficit Hyperactivity Disorder ADHD, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder GAD, Glioma, Neurodegenerative Diseases, Parkinson's Disease, Pervasive Developmental Disorder PDD, Schizophrenia, Smoking Addiction and Treatment Resistant Depression.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3

The report reviews Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Pipeline Review, H1 2018 [Report Updated: 20022018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Pipeline Review, H1 2018 [Report Updated: 20022018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...